Femina Pharma Incorporated
Records under this name other than patents Femina Pharma Incorporated holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Showing 1 to 9 of 9 · Back to Femina Pharma Incorporated
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,939,098 | Compositions and method for transmucosal drug delivery and cryoprotection Lapsed on the fee record Ended May 10, 2019 · USPTO record | Lapsed on the fee record | Ended May 10, 2019 | USPTO record |
| US 6,086,909 | Device and method for treatment of dysmenorrhea Formerly held Term ended Term ended Feb 12, 2019 · USPTO record | Term ended | Term ended Feb 12, 2019 | USPTO record |
| US 7,744,916 | Coated vaginal device for delivery of anti-migraine and anti-nausea drugs Lapsed on the fee record Ended Jun 29, 2018 · USPTO record | Lapsed on the fee record | Ended Jun 29, 2018 | USPTO record |
| US 6,197,327 | Device and method for treatment of dysmenorrhea Term ended Term ended May 15, 2018 · USPTO record | Term ended | Term ended May 15, 2018 | USPTO record |
| US 6,982,091 | Vaginal delivery of chemotherapeutic agents and inhibitors of membrane efflux systems for cancer therapy Lapsed on the fee record Ended Jan 3, 2018 · USPTO record | Lapsed on the fee record | Ended Jan 3, 2018 | USPTO record |
| US 6,905,701 | Formulations for transmucosal vaginal delivery of bisphosphonates Lapsed on the fee record Ended Jun 14, 2017 · USPTO record | Lapsed on the fee record | Ended Jun 14, 2017 | USPTO record |
| US 8,178,123 | Method for augmentation of intraepithelial and systemic exposure of therapeutic agents having substrate activity for cytochrome P450 enzymes and membrane efflux systems following vaginal and oral cavity administration Lapsed on the fee record Ended May 15, 2016 · USPTO record | Lapsed on the fee record | Ended May 15, 2016 | USPTO record |
| US 6,572,874 | Vaginal delivery of bisphosphonates Lapsed on the fee record Ended Jun 3, 2015 · USPTO record | Lapsed on the fee record | Ended Jun 3, 2015 | USPTO record |
| US 6,416,779 | Device and method for intravaginal or transvaginal treatment of fungal, bacterial, viral or parasitic infections Lapsed on the fee record Ended Jul 9, 2014 · USPTO record | Lapsed on the fee record | Ended Jul 9, 2014 | USPTO record |